公司概述
EUDA Health Holdings Limited operates within the Real Estate sector, specifically focusing on Real Estate Services, providing non-invasive healthcare solutions including bioenergy capsules, stem cell therapy, CRISPR gene editing treatments, and supplements alongside property management services. The company maintains a physical presence primarily in Singapore, Malaysia, and China, leveraging its diverse service portfolio to address emerging health needs across these jurisdictions. Currently, the firm employs a workforce of 117 individuals to support its operational activities and service delivery. With a total market capitalization of $13.48M and annual revenue of $5.16M, EUDA Health represents a micro-cap entity with limited scale relative to its peers. These valuation figures suggest the company is a small, niche player rather than a market leader, indicating that its revenue base is concentrated and potentially vulnerable to regional economic shifts or regulatory changes in its specific operating territories.
财务健康
The company reported a revenue of $5.16M over the trailing twelve months, yet this top-line figure masks significant operational inefficiencies as net income stands at -$2,064,341, revealing a cost structure where expenses substantially outweigh profitability. The EBITDA stands at -$1,992,526, further highlighting the struggle to cover core operational costs before financing and tax effects. Free cash flow is negative at -$3,350,164, which indicates a lack of financial flexibility and an inability to generate cash from operations to fund growth or repay obligations without external capital injection. The gross margin is 22.4%, suggesting that the core cost of goods sold consumes a significant portion of revenue, while the operating margin of -37.0% and profit margin of 5.2% demonstrate severe operating inefficiencies that are only partially offset by non-operating income. In terms of liquidity, the company holds $176,584 in cash against $2.28M in debt, creating a precarious balance sheet where obligations exceed liquid assets. The current ratio of 0.23 confirms a severe liquidity constraint, indicating that the company possesses only about 23% of the current assets necessary to cover its short-term liabilities. Return on Equity is listed as N/A due to the negative equity position, while Return on Assets is -63.9%, signaling that the asset base is generating substantial value destruction rather than returns for shareholders.
估值评估
The trailing twelve-month P/E ratio is 17.83, whereas the forward P/E is 4.46, a stark discrepancy that implies the market prices in a dramatic turnaround in earnings or relies heavily on non-GAAP adjustments to justify the current multiple. The price-to-book ratio stands at -3.57, which indicates that the stock trades at a significant discount to its book value, a metric often seen in distressed or loss-making companies where assets are undervalued or liabilities exceed equity. Alternative valuation metrics such as the price-to-sales ratio of 2.61 and EV/EBITDA of -7.70 suggest that traditional earnings-based valuations are inappropriate, forcing reliance on sales multiples that still reflect the company's unprofitable status. The stock's 52-week trading range spans from a low of $6.42 to a high of $86.00, illustrating extreme volatility and a wide spread that reflects market uncertainty regarding the company's future prospects. The beta value of 0.16 indicates that the stock price exhibits very low volatility relative to the broader market, moving significantly less than the benchmark despite its substantial price swings over the last year.
Growth & Income
Revenue growth year-over-year is 60.2%, while earnings growth is N/A due to the company's continued net losses, implying that top-line expansion has not yet translated into bottom-line profitability. The dividend yield is N/A with a payout ratio of 0.0%, confirming that the company does not distribute dividends to shareholders and instead retains any available cash flow, though in this case, it must rely on external financing. As a non-dividend payer, EUDA Health reinvests earnings into growth initiatives or raises capital to cover operational deficits rather than providing income to investors. The overall growth and income profile is characterized by rapid revenue expansion offset by persistent financial losses and a complete absence of dividend income, presenting a high-risk, high-potential-growth scenario typical of early-stage biotech or service firms.